Details

The trial is an open label extension study. Eligible patients from the RPC01-201, RPC01-301, and RPC01-1001 trials diagnosed with relapsing Multiple Sclerosis (RMS) will be enrolled to receive study drug until the end of the trial or until the Sponsor discontinues the development program.

Keywords

Multiple SclerosisMSRMSRelapsing Multiple SclerosisSclerosisRPC1063

Eligibility

For people ages 18-55

Eligibility Criteria:

Completed one of the parent trials: RPC01-201, RPC01-301 or RPC01-1001

Does not have a condition that would require withdrawal from one of the parent trials(RPC01-201, RPC01-301, RPC01-1001)

Has no conditions requiring treatment with a prohibited medication

Ability to provide written informed consent and to be compliant with the schedule of protocol assessments

Patients of reproduction potential (males and females) must practice an acceptable method of birth control